Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 13;17(1):84–95. doi: 10.1158/1535-7163.MCT-17-0705

Figure 5. In vivo acquired resistance of 1205LuTR GAL4-ELK1 xenografts to PLX8394.

Figure 5

A. Progressing xenografts were harvested and used to generate PLX8394 resistant cell lines (PBRTs). Crystal violet staining of PBRT #15 and #16 cells treated with increasing doses of PLX8394 compared to parental cells is shown. B. Quantified results of three independent experiments as in B. C. RPPA analysis of PBRT #15 and PBRT #16 cells compared to parental cells treated with either DMSO or PLX8394 (0.5 μM) for 24 hours. Heatmap showing proteins with a p value ≤ 0.01 and a fold change of ≥ 1.5 found to be significantly altered in PBRT #15 or #16 cells when compared to parental cells.